Acetylcholinesterase inhibitors used or tested in Alzheimer's disease therapy; their passive diffusion through blood brain barrier: In vitro study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10145974" target="_blank" >RIV/00179906:_____/13:10145974 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/13:43874855

Výsledek na webu

<a href="http://www.academicjournals.org/article/article1380887808_Karasova%20et%20al.pdf" target="_blank" >http://www.academicjournals.org/article/article1380887808_Karasova%20et%20al.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5897/AJPP2013.2977" target="_blank" >10.5897/AJPP2013.2977</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Acetylcholinesterase inhibitors used or tested in Alzheimer's disease therapy; their passive diffusion through blood brain barrier: In vitro study

Popis výsledku v původním jazyce

Although the information about Alzheimer's disease (AD) etiology is still unclear; acetylcholinesterase inhibitors still play a major role in symptomatic treatment of AD. Unfortunately, a relevant argumentation is complicated since information about realdrug concentration in the brain or timedependent blood-brain barrier (BBB) distribution studies are still quite rare. In this in vitro study, highperformance liquid chromatography (HPLC) method with special (IAM - immobilized artificial membrane) columnwas used to determine the ability of cholinesterase inhibitors to penetrate through BBB. Set of 8 structurally different cholinesterase inhibitors applicable to AD treatment was evaluated throughout this study. According to our method, all molecules areable to penetrate BBB by passive transport. However, some molecules such as huperzine A and galanthamine have lower ability to penetrate the BBB directly. These molecules may be delivered into the brain via active transport. Other molecu

Název v anglickém jazyce

Acetylcholinesterase inhibitors used or tested in Alzheimer's disease therapy; their passive diffusion through blood brain barrier: In vitro study

Popis výsledku anglicky

Although the information about Alzheimer's disease (AD) etiology is still unclear; acetylcholinesterase inhibitors still play a major role in symptomatic treatment of AD. Unfortunately, a relevant argumentation is complicated since information about realdrug concentration in the brain or timedependent blood-brain barrier (BBB) distribution studies are still quite rare. In this in vitro study, highperformance liquid chromatography (HPLC) method with special (IAM - immobilized artificial membrane) columnwas used to determine the ability of cholinesterase inhibitors to penetrate through BBB. Set of 8 structurally different cholinesterase inhibitors applicable to AD treatment was evaluated throughout this study. According to our method, all molecules areable to penetrate BBB by passive transport. However, some molecules such as huperzine A and galanthamine have lower ability to penetrate the BBB directly. These molecules may be delivered into the brain via active transport. Other molecu

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

African Journal of Pharmacy and Pharmacology

ISSN

1996-0816

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

22

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

1471-1481

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—